^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Padcev (enfortumab vedotin-ejfv)

    i
    Other names: ASG-22ME, AGS-22C3, AGS-22CE, AGS-22M6E, AGS-M6, ASG-22CE, ASG-22M6E, AGS22CE, AGS 22CE, AGS22M6E, AGS 22M6E, AGSM6, AGS M6, ASG 22ME, ASG-22ME, AGS 22C3, AGS 22ME, AGS22C3, AGS22ME, ASG 22CE, ASG22M6E, ASG 22M6E, ASG22ME
    Company:
    Astellas, Pfizer
    Drug class:
    Microtubule inhibitor, Nectin-4-targeted antibody-drug conjugate
    Related drugs:
    19h
    A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, Memorial Sloan Kettering Cancer Center
    New trial
    |
    Padcev (enfortumab vedotin-ejfv)
    20h
    Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304) (clinicaltrials.gov)
    P3, N=808, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Oct 2025 | Trial primary completion date: Dec 2026 --> Oct 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • cisplatin • gemcitabine • Padcev (enfortumab vedotin-ejfv)
    8d
    A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors (clinicaltrials.gov)
    P1/2, N=428, Recruiting, Astellas Pharma Global Development, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • STING (stimulator of interferon response cGAMP interactor 1)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • carboplatin • Padcev (enfortumab vedotin-ejfv)
    8d
    ENCORE: Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=34, Active, not recruiting, University of Utah | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Padcev (enfortumab vedotin-ejfv)
    8d
    SYS6002 vs PADCEV in Patients With Advanced Urothelial Carcinoma (clinicaltrials.gov)
    P2, N=100, Not yet recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd.
    New P2 trial
    |
    Padcev (enfortumab vedotin-ejfv)
    12d
    Preferred Treatment Sequencing for Metastatic Urothelial Carcinoma (mUC) in the Era of Perioperative and First-Line (1L) Checkpoint Inhibitor: Results From a National Survey of Genitourinary Oncologists. (PubMed, Clin Genitourin Cancer)
    Survey-based opinions can effectively capture treatment selection preferences for mUC and could inform future clinical trial design. Additional data, including the impact of residual toxicity from 1L EVP, are needed to better understand real-world treatment sequencing patterns.
    Journal • Checkpoint inhibition
    |
    FGFR3 (Fibroblast growth factor receptor 3)
    |
    Keytruda (pembrolizumab) • Balversa (erdafitinib) • Padcev (enfortumab vedotin-ejfv)
    14d
    Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer (clinicaltrials.gov)
    P1, N=32, Recruiting, Emory University | Trial primary completion date: Dec 2025 --> Nov 2026
    Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • Padcev (enfortumab vedotin-ejfv)
    15d
    MORPHEUS mUC: Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) (clinicaltrials.gov)
    P1/2, N=272, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • Tecentriq (atezolizumab) • gemcitabine • Zejula (niraparib) • Trodelvy (sacituzumab govitecan-hziy) • Padcev (enfortumab vedotin-ejfv) • magrolimab (ONO-7913) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • RG7827
    17d
    Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE) (clinicaltrials.gov)
    P2, N=68, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv)
    17d
    New insights into Nectin-4 expression in testicular choriocarcinoma and its potential treatment with Enfortumab Vedotin: analysis of a multi-institutional series and association with clinical-pathological features. (PubMed, Virchows Arch)
    These findings confirm that testicular CHC expresses Nectin-4 and may be potentially targetable with EV. Future studies are needed to verify whether metastasis and chemotherapy up-regulate Nectin-4 and increase the sensitivity to EV, and whether the absence of Nectin-4 expression by cytotrophoblasts (the proliferative population of CHC) influences its potential efficacy.
    Journal
    |
    NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    Padcev (enfortumab vedotin-ejfv)
    17d
    EV-4-EC: Study of EV for Recurrent Endometrial Carcinoma (clinicaltrials.gov)
    P2, N=12, Not yet recruiting, William Bradley | Initiation date: Nov 2025 --> Apr 2026
    Trial initiation date
    |
    NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    Padcev (enfortumab vedotin-ejfv)
    18d
    A zirconium-89-labeled antibody-drug conjugate PET probe for noninvasive monitoring of Nectin4 expression in breast cancer and lung cancer. (PubMed, Cell Rep Phys Sci)
    Minimal tumor uptake is observed in blocking and Nectin4-negative controls, confirming specificity. Complementary fluorescence imaging further reveals the in vivo distribution of Padcev, providing valuable insights into optimal therapeutic time windows.
    Journal
    |
    NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    Padcev (enfortumab vedotin-ejfv)